Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Drug Manufacturers - Specialty & Generic
NASDAQ:CRDL$1.23-5.38%| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 121.51M shares outstanding
CACardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD).
Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
Andrew Warwick Hamer
Chief Medical Officer and Head of Research & Development
David G. Elsley
President, Chief Executive Officer & Director
Bernard Lim
Chief Operating Officer
Christopher J. Waddick
Chief Financial Officer, Corporate Secretary & Director
Employees
18
Country
CA
Sector
Healthcare
Website
cardiolrx.com
Loading congressional disclosures…
based on 121.51M shares outstanding
CA30d Avg
1.63M
60d Avg
1.68M
90d Avg
1.47M
